Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > About Breakthrough T1D UK & our impact > Our research > Cure research > Vertex’s clinical trials of lab-grown insulin-making cells > VX-264 clinical trial
Placing islet cells within a protective coating is a technique called encapsulation. VX-264 refers to the therapy of surgically implanting these encapsulated cells into people with type 1 diabetes. The case is designed to protect the islet cells from both the autoimmune attack that causes type 1 and the immune response to new cells entering the body.
Vertex researchers are testing whether VX-264 can treat people with type 1 diabetes. Thanks to the protective coating, the participants don’t need to take immunosuppressants.
The therapy has already been through lots of testing in other species to make sure it is as safe as possible. This trial is a first-in-human study, where researchers find out a safe and effective dose to give people and identify any side effects. Each new participant is given the treatment a short while after the last person to ensure they haven’t experienced any serious side effects.
The scientists running this study are recruiting 17 people with type 1 diabetes. People who experience repeated severe hypos aren’t eligible for this trial. As the scientists learn more about how safe this treatment is, they hope to extend the trial to a wider population of people with type 1, including more vulnerable people.
This international trial is currently running in the US, Canada and the Netherlands, with Vertex planning to expand to additional sites.
Find out if you’re eligible to take part in the VX-264 clinical trial.
The researchers have recruited several people and given the first participants in this trial a dose of the encapsulated lab-grown islet cells. The study is ongoing, with more people being given the VX-264 therapy and monitored to see their effects. It is too early to have any results yet, but we will keep this page updated as the findings are announced.
Learn about how researchers are trying to find a cure for type 1.
Discover our research to improve and develop treatments for type 1.
Learn how Breakthrough T1D UK-funded researchers are trying to prevent type 1 diabetes.
Your donations help us fund innovative research projects across the world, giving us the best chance of finding a cure. Together, we will make a world without type 1.
